As an alternative to coagulation therapies, especially in ROP, anti-VEGF therapy allows easier administration under topical anesthesia and preserves the peripheral retina, which avoids the risk of visual field defects associated with photocoagulation [94]. Here, VEGFA is linked to retinopathy of prematurity.